Answer
Tagrisso (osimertinib mesylate) increased rosuvastatin AUC by 35% and peak plasma concentration (Cmax) by 72% when co-administered in a clinical pharmacokinetic study.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 32Document updated
Sources checked